MARKET

CBIO

CBIO

Catalyst Biosciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.39
+0.02
+0.37%
After Hours: 5.53 +0.14 +2.60% 17:48 08/07 EDT
OPEN
5.39
PREV CLOSE
5.37
HIGH
5.51
LOW
5.30
VOLUME
152.69K
TURNOVER
--
52 WEEK HIGH
8.94
52 WEEK LOW
3.430
MARKET CAP
118.77M
P/E (TTM)
-1.4913
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CBIO stock price target is 20.50 with a high estimate of 23.00 and a low estimate of 19.00.

EPS

CBIO News

More
Catalyst Biosciences Reports Second Quarter 2020 Operating & Financial Results and Provides a Corporate Update
GlobeNewswire · 1d ago
Chembio Shares Spike; Co. Wins $628K Contract From Health And Human Services
https://beta.sam.gov/opp/fab9b173a9eb4508a6fa6272d24ee998/view?keywords=&sort=-modifiedDate&index=&is_active=true&page=1
Benzinga · 07/15 17:40
Catalyst Biosciences Presents Data At The International Society For Thrombosis And Haemostasis Virtual Congress
Catalyst Biosciences Presents Data at the International Society for Thrombosis and Haemostasis (ISTH) Virtual Congress Subcutaneous marzeptacog alfa (activated) (MarzAA) rapidly achieves and maintains therapeutic
Benzinga · 07/13 12:09
Does Catalyst Biosciences' (NASDAQ:CBIO) Share Price Gain of 34% Match Its Business Performance?
Simply Wall St. · 07/09 14:48
Hedge Funds Still Very Bullish On Catalyst Biosciences Inc (CBIO)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter
Insider Monkey · 07/08 01:28
Catalyst Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 07/01 21:48
Catalyst Biosciences Announces Presentations at the International Society on Thrombosis and Haemostasis
GlobeNewswire · 06/29 13:00
Catalyst Biosciences Added to Russell 2000 Index
GlobeNewswire · 06/29 13:00

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About CBIO

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company's advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.
More

Webull offers kinds of Catalyst Biosciences Inc stock information, including NASDAQ:CBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CBIO stock methods without spending real money on the virtual paper trading platform.